IBI-302 is a Fusion Protein owned by Innovent Biologics, and is involved in 6 clinical trials, of which 2 were completed, 3 are ongoing, and 1 is planned.

IBI-302 is a bi-specific fusion protein that inhibits the activation of complement pathway(C3b and C4b) and the expression of vascular endothelial growth factor (VEGF) , inflammation-related molecules including TNF-alpha, CCL-2. This leads to inhibition of the infiltration of macrophages and neutrophils and the deposition of membrane-attack-complex.

The revenue for IBI-302 is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the IBI-302 NPV Report.

IBI-302 is originated and owned by Innovent Biologics.

IBI-302 Overview

IBI-302 is under development for the treatment of wet age-related macular degeneration, retinal fibrosis, macular atrophy and diabetic macular edema. It is a bi-specific fusion protein that targets VEGF expression and complement factor (C3b and C4b). It was also under development for metabolic diseases and solid tumors. It is administered through intravitreal and intraocular route.

Innovent Biologics Overview

Innovent Biologics is a biopharmaceutical company that focuses on the research, development and manufacturing of monoclonal antibodies. It provides products for various diseases such as metabolic, cancer, autoimmune diseases and other therapeutic areas. The company oncology products include sintilimab injection, bevacizumab injection, rituximab injection, pemigatinib, olverembatinib, ramucirumab, and others. Its autoimmune drugs are adalimumab injection, IBI-353, IBI-112, IBI-314, among others. The company’s metabolic and ophthalmology products include IBI-306, IBI-362, IBI-302, IBI-324, IBI-311

The company reported revenues of (Renminbi) CNY4,269.7 million for the fiscal year ended December 2021 (FY2021), an increase of 11.1% over FY2020. The operating loss of the company was CNY2,988.6 million in FY2021, compared to an operating loss of CNY790.4 million in FY2020. The net loss of the company was CNY3,138.1 million in FY2021, compared to a net loss of CNY998.4 million in FY2020.

Quick View – IBI-302

Report Segments
  • Innovator
Drug Name
  • IBI-302
Administration Pathway
  • Intraocular
  • Intravitreal
Therapeutic Areas
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.